Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer’s disease - 18/03/26
, Zachary Sheff 1 , Nalin Payakachat 1 , Julie M. Chandler 1 , Yun-Fei Chen 1 , Joanna Kubisiak 2 , Angelina Lee 2 , Karen C. Holdridge 1 , Roy Yaari 1 , Paul Aisen 3 , Michael S. Rafii 3 , Reisa A. Sperling 4 for the
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Alzheimer’s disease (AD) begins with the preclinical stage (Stage 1 and 2) where individuals are cognitively unimpaired but have AD pathology. Healthcare utilization and medical cost of preclinical AD have not been previously evaluated.
Objectives |
To describe healthcare resource utilization (HRU) and Medicare payments among cognitively unimpaired individuals with and without elevated amyloid and to evaluate the association of AD progression with HRU and Medicare payments.
Design |
Retrospective cohort analysis of the randomized controlled trial (Anti-Amyloid Treatment in Asymptomatic AD [A4]) and companion observational study (Longitudinal Evaluation of Amyloid Risk and Neurodegeneration [LEARN]) linked with Medicare.
Setting |
Clinical trials sites in the United States
Participants |
246 cognitively unimpaired participants with preclinical AD in A4 and 121 amyloid-negative participants in LEARN Medicare cohorts.
Measurements |
Measures from Medicare claims included medical conditions (diagnosis codes), HRU (inpatient, emergency room, outpatient, professional, skilled nursing facility, home health), and Medicare payments. AD progression (or cognitive or functional decline) was measured using Clinical Dementia Rating Scale-Global Score (CDR-GS) in A4/LEARN and diagnosis codes for cognitive impairment, AD, and JEN Frailty Index (JFI) of ≥6 (high frailty) in Medicare data.
Results |
HRU and payments were overall similar between A4 and LEARN Medicare. Claims indicators suggesting AD progression in A4 Medicare were associated with higher inpatient, outpatient, emergency room, and home health utilization (any utilization) and increased number of inpatient stays. Payments were significantly greater in A4 Medicare with AD progression vs without progression: 45% payment increase for cognitive impairment (p=0.035) with a mean incremental cost of $140 per person per month (PPPM) (95% confidence interval [CI] $125-$155), 66% payment increase for AD (p=0.011) with a mean incremental cost of $207 PPPM (95% CI $188-$226), and 103% payment increase for high frailty (p<0.001) with a mean incremental cost of $303 PPPM (95% CI $283-$323).
Conclusions |
Overall, individuals with preclinical AD in A4 Medicare did not have increased utilization and payments vs LEARN. HRU and payments were significantly greater in A4 Medicare participants with AD progression indicators in claims vs those without progression. These results highlight the need for additional research on both health and economic impacts of progression in a real-world (routine care) cohort of individuals with preclinical AD and the potential cost savings associated with effective therapy that delays AD progression in preclinical AD.
Clinical trial registration information |
NCT02008357, NCT02488720
Le texte complet de cet article est disponible en PDF.Keywords : A4, LEARN, Alzheimer’s disease, preclinical AD, health resource utilization, AD disease progression, Medicare
Plan
| Presented, in part, at Alzheimer’s Association International Conference (AAIC); July 28-August 1, 2024; Philadelphia, PA, USA, and Online and Alzheimer’s Association International Conference (AAIC); July 27-30, 2025; Toronto, Canada |
Bienvenue sur EM-consulte, la référence des professionnels de santé.